PROMIS NEUROSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 USD | -1.96% |
|
-0.66% | +30.43% |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.57 | 50.45 | 28.77 | 38.93 | - | - |
| Enterprise Value (EV) 1 | 47.57 | 50.45 | 28.77 | 38.93 | 38.93 | 38.93 |
| P/E ratio | - | - | -1.05 x | -2.87 x | -2.18 x | -1.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 39,642 x | - | - | - | - | - |
| EV / Revenue | 39,642 x | - | - | - | - | - |
| EV / EBITDA | - | -1.6 x | - | -1.08 x | -1.3 x | -1.27 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,590 | 8,579 | 18,885 | 18,961 | - | - |
| Reference price 2 | 10.36 | 5.880 | 1.523 | 2.053 | 2.053 | 2.053 |
| Announcement Date | 18/03/20 | 08/03/23 | 01/04/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0012 | - | - | - | - | - | - |
| EBITDA 1 | - | - | -31.54 | - | -35.98 | -29.87 | -30.55 |
| EBIT 1 | -7.396 | - | -32.23 | -19.36 | -23.33 | -33.79 | -46.44 |
| Operating Margin | -616,355% | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.396 | - | - | -17.94 | -23.06 | -36.33 | -60.8 |
| Net income 1 | -7.396 | -11.78 | -24.9 | -17.94 | -23.06 | -34.12 | -46.62 |
| Net margin | -616,355% | - | - | - | - | - | - |
| EPS 2 | - | - | - | -1.453 | -0.7160 | -0.9425 | -1.140 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 18/03/20 | 17/03/22 | 08/03/23 | 01/04/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -3.904 | -3.454 | -5.26 | - | -5.576 | -6.092 | -6.608 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.239 | -4.861 | - | -5.565 | -5.982 | -6.513 |
| Net income 1 | -3.113 | -3.239 | -4.861 | -4.962 | -5.565 | -5.982 | -6.513 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | - | -0.2607 | -0.1222 | -0.2593 | -0.1930 | -0.1510 | -0.1650 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 14/08/23 | 14/11/23 | 01/04/24 | 14/05/24 | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 18/03/20 | 17/03/22 | 08/03/23 | 01/04/24 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.053
CAD
Average target price
12.03
CAD
Spread / Average Target
+486.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.43% | 29.01M | |
| +15.20% | 122B | |
| +19.67% | 113B | |
| +18.95% | 26.49B | |
| -23.86% | 19.4B | |
| -19.03% | 16.24B | |
| -20.90% | 15.4B | |
| -46.14% | 15.15B | |
| +63.85% | 14.93B | |
| +4.49% | 13.52B |
- Stock Market
- Equities
- PMN Stock
- Financials ProMIS Neurosciences, Inc.
